Ilyang Pharmaceutical announced on March 27 that it will start clinical trials in Europe to develop its self-developed drug into a Parkinson's disease (PD) treatment.
Ilyang Pharmaceutical recently held a briefing on pre-clinical results at a clinical hospital in France to conduct clinical trials in Europe. In addition, the company signed a contract with a clinical CRO hospital in France based on the animal test data conducted at the Johns Hopkins Medical School in the United States and the pre-clinical results conducted in Japan for six months. The company plans to carry out clinical trials in European countries, including France, from the second half of this year.
These clinical trials for PD treatment development can carry out phases one and two at the same time. This will significantly shorten the time required for clinical trials and Ilyang has already undergone several preliminary checks on candidate substances for clinical trials. Conventional PD treatments only relieve symptoms and slow down the progression in terms of effectiveness, and globally, pharmaceutical companies avoid developing new PD treatments due to complicated tests and high risks.
Ilyang Pharmaceutical disclosed that the director of the European Parkinson’s Disease Association will lead this study.
The candidate material that Ilyang selected for the new PD treatment has been presented at the Society for Neuroscience (SFN) and is a substance that effectively inhibits the aggregation of α-synuclein, a major causal factor of PD, in the brain. Study results on the substance have been published in SCI international journal Human Molecular Genetics.